Latest Headlines

Latest Headlines

Don't blame industry trends for Sandoz's slide, analyst says. But biosimilars? Maybe

Last week, Novartis' Sandoz unveiled weak numbers, blaming them on broader generics-industry trends. But at least one analyst isn't convinced that's the culprit.

Perrigo, already recalling Zyrtec copy, now recalling knockoff of Mucinex for children

Over-the-counter specialist Perrigo said on Monday that it was recalling some of its children's grape-flavored Mucinex copies after learning that dosing cups may be mismarked, putting children at risk for being overdosed. It said for some children, taking too much of the med could lead to vomiting and other stomach problems.

Industry Voices: Navigating Uncharted Territory--Understanding Product Liability Risks in Biosimilars

The launch of the first biosimilar in the U.S., Sandoz's Zarxio, has stimulated tremendous market opportunities, with sales predictions for biosimilars pointing to $25 billion by 2020, according to a 2014 Thomson Reuters report.

Novartis' Sandoz plants in India cited in warning letter

Novartis said on Tuesday in its earnings announcement that two Sandoz plants in India had been nailed last week with a warning letter. CEO Joseph Jimenez said the FDA issued the warning letter for the sites in Kalwe as well as one in Turbhe, a plant that Sandoz intends to close.

Novartis to close one Indian manufacturing plant as FDA warning bites

Swiss-based Novartis will close a manufacturing plant in India, CEO Joe Jimenez said on the Oct. 27 third quarter earnings call, noting that the company has moved on remediation plans following inspections, but still received a U.S. FDA warning letter.

Novartis opens Austria plant as part of its biosimilars push

Two weeks ago, Novartis launched a copy of Amgen's Neupogen (filgrastim), its first in what it expects to be a thriving business in biosimilars, in the U.S. In anticipation of big sales, its Sandoz unit has now opened a plant in Austria to make the autoinjectors that will dispense the drugs.

Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do?

The age of biosimilars in the U.S. has finally dawned with the launch of Novartis' Zarxio, a copy of Amgen's Neupogen (filgrastim). And it's arriving with a 15% discount to win scripts over from the brand.

Novartis whacks 3 Sandoz plants, 770 jobs, despite generic units' sales growth

A 10% revenue expansion in Novartis' generics unit Sandoz was one of the positives in the Swiss drugmaker's second quarter earnings, but it will not keep the drugmaker from closing three Sandoz plants next year and cutting about 770 jobs to improve margins even more.

Sandoz gives Novartis a boost, but 3 plants still get the boot

Novartis's generics business Sandoz provided the key bright spot in an otherwise tough earnings report for the Swiss pharma, with revenues up 10%. But the starring performance did not keep the manufacturing side of Sandoz from getting spanked, with three of its plants now targeted for closing.

Amgen's Neupogen won't face Novartis biosim till September: court

Novartis' Sandoz may have the first FDA-approved biosimilar in Zarxio, but it doesn't have permission to launch--and it won't be getting that until September, the country's top patent court ruled Tuesday.